Narcolepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 109 pages | ID: NE1AE830CA1DEN
Global Markets Direct

Abstracts

Narcolepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Drugs In Development, 2022, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 9 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Narcolepsy - Overview
Narcolepsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Narcolepsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Narcolepsy - Companies Involved in Therapeutics Development
Axsome Therapeutics Inc
Bioprojet SCR
Centessa Pharmaceuticals Plc
ConSynance Therapeutics Inc
F. Hoffmann-La Roche Ltd
Gubra ApS
Inexia Ltd
Jazz Pharmaceuticals Plc
KemPharm Inc
Lennham Pharmaceuticals Inc
NLS Pharmaceutics AG
Ono Pharmaceutical Co Ltd
Seelos Therapeutics, Inc.
SK Biopharmaceuticals Co Ltd
Sumitomo Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Suven Life Sciences Ltd
Synchronicity Pharma Inc
Takeda Pharmaceutical Co Ltd
Theranexus SA
Vallon Pharmaceuticals Inc
XWPharma Ltd
Narcolepsy - Drug Profiles
(flecainide acetate + modafinil) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALKS-2680 - Drug Profile
Product Description
Mechanism Of Action
History of Events
danavorexton - Drug Profile
Product Description
Mechanism Of Action
History of Events
dextroamphetamine IR - Drug Profile
Product Description
Mechanism Of Action
History of Events
DSP-0187 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GUI-36 - Drug Profile
Product Description
Mechanism Of Action
HBS-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KP-1077 - Drug Profile
Product Description
Mechanism Of Action
mazindol ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
NLS-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NLS-4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ONO-2909 - Drug Profile
Product Description
Mechanism Of Action
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
OX2 agonist - Drug Profile
Product Description
Mechanism Of Action
History of Events
OX2 agonist (Oral) - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oxybate - Drug Profile
Product Description
Mechanism Of Action
Peptides to Agonize Orexin 2 Receptor for Narcolepsy and Unspecified Neurologic Disorders - Drug Profile
Product Description
Mechanism Of Action
pitolisant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
reboxetine - Drug Profile
Product Description
Mechanism Of Action
History of Events
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
History of Events
samelisant - Drug Profile
Product Description
Mechanism Of Action
History of Events
SLS-010 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize ADORA for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
solriamfetol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-861 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-994 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ulotaront - Drug Profile
Product Description
Mechanism Of Action
History of Events
valiloxybate - Drug Profile
Product Description
Mechanism Of Action
History of Events
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
Narcolepsy - Dormant Projects
Narcolepsy - Discontinued Products
Narcolepsy - Product Development Milestones
Featured News & Press Releases
Jul 21, 2022: NLS pharmaceutics announces positive opinion from European Regulators to grant Orphan Drug Designation for Mazindol ER in idiopathic hypersomnia
Jun 28, 2022: Axsome Therapeutics hosts Sunosi investor update virtual event today with Key Opinion Leaders
Jun 28, 2022: Axsome Therapeutics to host Sunosi investor update virtual event
Jun 08, 2022: Harmony Biosciences presents post-hoc analysis of WAKIX (pitolisant) pivotal data in adults with high burden of narcolepsy symptoms
Jun 02, 2022: NLS Pharmaceutics announces over enrollment in its phase 2a clinical trial evaluating Quilience(R) for the treatment of narcolepsy
May 12, 2022: Vallon Pharmaceuticals reports additional pharmacokinetic and pharmacodynamic data from SEAL study of ADAIR
May 04, 2022: NLS Pharmaceutics achieves 90% enrollment milestone in Quilience phase 2a clinical trial for patients with narcolepsy
Mar 28, 2022: NLS Pharmaceutics announces Early Access Program (EAP) allowing patients with idiopathic hypersomnia to receive treatment with Mazindol ER
Mar 16, 2022: NLS Pharmaceutics announces positive interim top-line data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
Feb 23, 2022: KemPharm completes KP1077 Pre-IND meeting process with FDA
Feb 07, 2022: NLS Pharmaceutics to present interim top-line data for Quilience (Mazindol ER) in patients with narcolepsy at the World Sleep Congress in March 2022
Feb 07, 2022: Aculys Pharma begins Japan PI for narcolepsy drug candidate
Dec 13, 2021: Harmony Biosciences publishes pitolisant efficacy data in CNS Drugs
Nov 18, 2021: National Institute for Health and Care Excellence (NICE) issues positive guidance for Jazz Pharmaceuticals' Sunosi (solriamfetol) for the treatment of adults with excessive daytime sleepiness (EDS) caused by narcolepsy
Oct 06, 2021: Takeda to stop Phase II trials of TAK-994 due to safety signal
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Narcolepsy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Narcolepsy - Pipeline by Axsome Therapeutics Inc, 2022
Narcolepsy - Pipeline by Bioprojet SCR, 2022
Narcolepsy - Pipeline by Centessa Pharmaceuticals Plc, 2022
Narcolepsy - Pipeline by ConSynance Therapeutics Inc, 2022
Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Narcolepsy - Pipeline by Gubra ApS, 2022
Narcolepsy - Pipeline by Inexia Ltd, 2022
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, 2022
Narcolepsy - Pipeline by KemPharm Inc, 2022
Narcolepsy - Pipeline by Lennham Pharmaceuticals Inc, 2022
Narcolepsy - Pipeline by NLS Pharmaceutics AG, 2022
Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Narcolepsy - Pipeline by Seelos Therapeutics, Inc., 2022
Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
Narcolepsy - Pipeline by Sumitomo Pharma Co Ltd, 2022
Narcolepsy - Pipeline by Sunovion Pharmaceuticals Inc, 2022
Narcolepsy - Pipeline by Suven Life Sciences Ltd, 2022
Narcolepsy - Pipeline by Synchronicity Pharma Inc, 2022
Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Narcolepsy - Pipeline by Theranexus SA, 2022
Narcolepsy - Pipeline by Vallon Pharmaceuticals Inc, 2022
Narcolepsy - Pipeline by XWPharma Ltd, 2022
Narcolepsy - Dormant Projects, 2022
Narcolepsy - Dormant Projects, 2022 (Contd..1)
Narcolepsy - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Narcolepsy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022